ГоловнаArchive of numbers2017Volume 25, issue 1 (90)Clinical and pharmaceutical analysis of neuroprotective drugs usage in patients with dyscirculatory encephalopathy
Title of the article Clinical and pharmaceutical analysis of neuroprotective drugs usage in patients with dyscirculatory encephalopathy
Authors Moroz Volodymyr
Grintsov Yevhen
Golianishchev Maxym
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL AND MENTAL DISORDERS
Year 2017 Issue Volume 25, issue 1 (90) Pages 59-61
Type of article Scientific article Index UDK 616.831: 616-085.2 /.3: 615.065 Index BBK -
Abstract The paper studies the rational use of neuroprotective drugs in terms of the course medical treatment of dyscirculatory encephalopathy (DEP). Performed clinical and pharmaceutical analysis of 127 history of the inpatient disease with DEP in age from 50 to 75 years (35 men and 92 women). The analysis was performed on basis of approved health care protocols, taking into account the various aspects of the rational use of neuroprotective drugs: their dosage, pharmacological and pharmaceutical compatibility, contraindications, side eff ects, etc. On whole, it was appointed 13 neuroprotective drugs in 334 cases. In 70 cases (21.0 % of prescriptions) set the irrationality of their application. In particular, piracetam (57 prescriptions) was administered on background of low blood pressure in 15.8 % of cases and in 19.3 % caused dyssomnias. The last side eff ect is also observed for meldonium (13.7 % of the 51 prescriptions), which also was used in 23.5 % of cases in the background tachycardia of different genesis. Among the 37 prescriptions of pyritinol in 13.5 % of cases was used in patients with concomitant cholelithiasis. What is devoid of rationality due to the ability of the drug to cause severe cholestasis. Certain discrepancies identifi ed in cases prescriptions of thiotriazoline, ginkgo biloba drugs, tocopherol, ergocalciferol, GABA, inosine and drug of ATP. In addition to the irrational use of drugs, detected 38 cases (11.4 % of prescriptions) of the associated side eff ects. To enhance the effi ciency of drug therapy in patients with DEP requires a more thorough analysis of the planned and carried out pharmacotherapy with the participation in the treatment process of the clinical pharmacist.
Key words clinical and pharmaceutical analysis, neuroprotective drugs, dyscirculatory encephalopathy, rational combination of drugs
Access to full text version of the article pdf download
Bibliography 1. Табеева Г. Р. Дисциркуляторная энцефалопатия: основные мишени терапии // Фарматека. 2010. № 5. С. 18—24.
2. Асташкин Е. И., Глезер М. Г. Дисциркуляторная энцефалопатия: клиника, диагностика и возможности терапии // Там же. 2015. № 9. С. 88—95.
3. Мороз В. А. Дисциркуляторная энцефалопатия: современные подходы к лечению и профилактике // Провизор. 2008. № 9. С. 20—23.
4. Güngör L., Terzi M., Onar M. K. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? // Brain Lang. 2011. № 1 (117). P. 23—27.
5. Клінічний протокол надання медичної допомоги хворим на дисциркуляторну енцефалопатію // Медичний індекс. Терапія. 2008. № 1. C. 10—11.
6. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia / D. T. Lau, N. D. Mercaldo, J. W. Shega [et al.] // Am J Alzheimer's Dis Other Demen. 2011. № 26 (8). P. 606—615.
7. Азимова Ю. Э. Подходы к лечению дисциркуляторной энцефалопатии: от полипрагмазии к рациональной комбиниро- ванной терапии // Эффективная фармакотерапия. Неврология. 2010. № 5. С. 26—30.
8. Real-world analysis of concurrent diseases and medicine use among patients with insomnia / J. F. Cui, W. Yang, Y. M. Xie [et al.] // Zhongguo Zhong Yao Za Zhi. 2014. № 18 (39). P. 3519—3526.
9. Место мельдония в метаболической цитопротекции / В. С. Задионченко, Г. Г. Шехян, А. А. Ялымов [и др.] // РМЖ. 2013. № 9. С. 448—453.
10. Drug-induced acute pancreatitis: an evidence-based review / N. Badalov, R. Baradarian, K. Iswara [et al.] // Clin. Gastroenterol. Hepatol. 2007. № 6 (5). P. 648—661.
11. Компендиум 2015 — лекарственные препараты / под ред. В. Н. Коваленко. Киев : Морион, 2015. 1408 с.
12. Harrison F. E., Bowman G. L., Polidori M. C. Ascorbic Acid and the Brain: Rationale for the Use against Cognitive Decline // Nutrients. 2014. № 4 (6). P. 1752—1781.
13. Antioxidant Capacity of Lenses with Age-Related Cataract (Electronic Resource) / B. Kisic, D. Miric, L. Zoric, A. [et al.] // Oxid Med Cell Longev. 2012. Article ID 467130. URL : https://www.hindawi. com/journals/omcl/2012/467130/.
14. Sophie Pilon. Essential drugs. Practical guidelines intended for physicians, pharmacists, nurses and medical auxiliaries / ed. V. Grouzard. WHO: Médecins Sans Frontières, 2013. 376 p.